コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 en 85B further enhances immune responses and protective efficacy.
2 ed, this singular approach can yield limited protective efficacy.
3 eportedly erodes proliferative potential and protective efficacy.
4 faster, to higher titers, and with improved protective efficacy.
5 didate that enhances both TH1 generation and protective efficacy.
6 tant role than others in determining vaccine protective efficacy.
7 with long interdose periods and provides low protective efficacy.
8 monstrate emergent properties with regard to protective efficacy.
9 e, however, not yet matched whole sporozoite protective efficacy.
10 red the mucosal immune responses and vaccine protective efficacy.
11 minidase (NA) have to be updated for optimal protective efficacy.
12 nt isotypes manifest profound differences in protective efficacy.
13 ficant antigen-sparing effects with improved protective efficacy.
14 require two or three immunisations for full protective efficacy.
15 imal to evaluate immunogenicity, safety, and protective efficacy.
16 33 MAb and anti-B5 MAb did not synergize the protective efficacy.
17 nctional mechanism for their contribution to protective efficacy.
18 or development of PRRSV vaccines of enhanced protective efficacy.
19 able to wild-type HMPV in immunogenicity and protective efficacy.
20 rtussis, vaccine safety, immunogenicity, and protective efficacy.
21 ponse is considered critical for HIV vaccine protective efficacy.
22 um salts may not be potent enough to achieve protective efficacy.
23 tors has an impact on the memory profile and protective efficacy.
24 vaccines because of high immunogenicity and protective efficacy.
25 c fitness, longevity, polyfunctionality, and protective efficacy.
26 y the rBCG vaccine candidate relevant to its protective efficacy.
27 ning CS may result in a significant clinical protective efficacy.
28 ovel combination of antibodies with enhanced protective efficacy.
29 wild-type H7N9 virus to assess the vaccine's protective efficacy.
30 d in augmented immune responses and improved protective efficacy.
33 acity of the boosting antigen influences the protective efficacy afforded by prime-boost vaccine regi
34 he detailed kinetics of immune responses and protective efficacy after a single intranasal immunizati
36 c--and were evaluated for immunogenicity and protective efficacy against a highly lethal intraperiton
37 xture of CD4-CD8 lipopeptide vaccine and the protective efficacy against acute virus replication and
38 hese candidate vaccine strains showed strong protective efficacy against AHSV infection in an IFNAR(-
42 on of primary prostatic tumor and also shows protective efficacy against angiogenesis and late stage
43 CD4(+) T cell responses are associated with protective efficacy against blood-stage malaria, whereas
44 abbit antibody to PMA-FLA showed evidence of protective efficacy against both types of this organism
45 r and humoral immune responses and increased protective efficacy against challenge with recombinant v
46 n chi9241 also induced significantly greater protective efficacy against challenge with virulent S. p
47 ein of Plasmodium falciparum and has partial protective efficacy against clinical and severe malaria
48 cine that affords in the neighborhood of 50% protective efficacy against clinical malaria is in the l
49 hich is a notable achievement, its long-term protective efficacy against each of the 4 dengue virus s
51 age antigen(s) alone has induced significant protective efficacy against erythrocytic-stage infection
52 mice and guinea pigs for immunogenicity and protective efficacy against genital challenge with wild-
53 nes demonstrated superior immunogenicity and protective efficacy against H7N9 infection in ferrets an
55 he only vaccine approach shown to elicit any protective efficacy against HIV-1 acquisition is based o
57 h level of neutralizing serum antibodies and protective efficacy against HMPV; AMPV was only weakly i
58 evels and cellular immune responses, and the protective efficacy against homologous and heterologous
59 ) CFU with the mutant to evaluate safety and protective efficacy against intraperitoneal and aerosol
60 ole in attenuating diarrhea and in providing protective efficacy against intraperitoneal Shigella inf
62 CD47KO mice with vaccination showed greater protective efficacy against lethal challenge, as evidenc
63 tested using opsonophagocytic assays and for protective efficacy against lethal peritonitis in mice.
66 quine encephalitis virus (VEEV) demonstrated protective efficacy against Marburg virus in nonhuman pr
69 sity on vaccine-induced immune responses and protective efficacy against pandemic H1N1 influenza viru
75 ent pan-ebolavirus neutralizing activity and protective efficacy against three virulent ebolaviruses.
76 ly, the mutant's virulence potential and its protective efficacy against type A and type B strains we
77 , diminished antibody responses, and reduced protective efficacy against wild-type virus challenge fo
78 ults in a vaccine with a 20-fold decrease in protective efficacy and a 10,000-fold increase in safety
79 effectiveness has been hindered by variable protective efficacy and a lack of lasting memory respons
80 Coxiella burnetii infection, we compared the protective efficacy and immunogenicity between formalin-
82 e skin using a microneedle patch can improve protective efficacy and induce long-term sustained immun
83 nt quantity can be achieved while maximizing protective efficacy and preserving proliferative potenti
84 ) (VRC-10-332) that demonstrated substantial protective efficacy and revealed a genetic signature of
86 the scarcity of pre-clinical models to test protective efficacy and support further clinical trials.
87 ly distinct GAPs confer different degrees of protective efficacy and that live vaccine persistence in
88 double-knockout Pbuis3(-)/4(-) parasites for protective efficacy and the contribution of CD8(+) T cel
89 et because of its documented immunogenicity, protective efficacy, and antifecundity effects observed
90 igated their immunogenicity, long-term cross-protective efficacy, and effects on lung proinflammatory
93 enicity in M. tuberculosis-naive animals and protective efficacy as measured by a reduction in lung M
94 infected cells, contributes substantially to protective efficacy at early and late time points postim
96 lective TLR ligand combinations can increase protective efficacy by increasing the quality rather tha
99 serogroups were associated with the highest protective efficacy compared to vaccines with fewer comp
100 d that the backbone-specific MAb had optimal protective efficacy compared with the acetate-specific M
103 activity of the elicited antibodies, and the protective efficacy elicited in mice immunized with the
104 ve examined infectivity, immunogenicity, and protective efficacy following infection with a replicati
106 opulation characteristics that may relate to protective efficacy have received little attention.
108 ch anti-HIV-1 envelope Abs can contribute to protective efficacy.IMPORTANCE Anti-V2 antibodies (Abs)
111 terleukin-17 secretion and provided a higher protective efficacy in a mouse challenge model than did
113 appropriate for assessing immunogenicity and protective efficacy in animal models and in human trials
116 V glycoproteins for their immunogenicity and protective efficacy in cotton rats and African green mon
117 vaccine candidate, which showed significant protective efficacy in endemic populations in Guinea.
119 inants were evaluated for immunogenicity and protective efficacy in hamsters, which support a high le
123 d traditional tools, this study compares the protective efficacy in macaques of an intrarespiratory l
125 lts demonstrated safety, immunogenicity, and protective efficacy in mice and nonhuman primates (NHPs)
132 own ebolavirus species in vitro and show its protective efficacy in mouse models of ebolavirus infect
133 tional analogs of P7C3 correlates with their protective efficacy in MPTP-mediated neurotoxicity.
135 experiments proved this vaccine candidate's protective efficacy in pigs and the promise to control c
136 ) were selected and evaluated for safety and protective efficacy in pigs by comparison with a commerc
138 s study, we evaluated the immunogenicity and protective efficacy in rabbits of multiple antigenic pep
141 oproteins (VSVDeltaG/Dual) and evaluated its protective efficacy in the common lethal Syrian hamster
142 nt in native conformation that provide cross-protective efficacy in the prevention of meningococcal d
143 ing whether there may, or may not, have been protective efficacy in the RV144 vaccine trial have impo
144 er of immunizations with CTB could influence protective efficacy in the suckling mouse model of chole
148 cles (VRP) was tested for immunogenicity and protective efficacy in weanling mice in the presence and
149 on with the recombinant Ad5/3 vector induces protective efficacy indistinguishable from that elicited
152 Although both vaccines demonstrated cross-protective efficacy, LAIV induced higher levels of nasal
155 with P. berghei sporozoites to determine the protective efficacies of different vaccine regimens.
156 onatal gnotobiotic pig model to evaluate the protective efficacies of primary infection, P particles,
157 comparison of the immunogenic properties and protective efficacies of the different forms of hRSV F w
159 moderate-transmission site, mefloquine had a protective efficacy of 38.1% (95% CI 11.8-56.5, p=0.008)
161 ompared in vitro and in vivo the potency and protective efficacy of 5C4 and the murine precursor of p
164 ansgenic (HLA Tg) rabbit model to assess the protective efficacy of a human CD8(+) T cell epitope-bas
167 malaria-naive adults in order to define the protective efficacy of a malaria vaccine and thus guide
168 Here, we examined the immunogenicity and protective efficacy of a recombinant GBS BCP (rBCP), an
169 We investigated the scope for enhancing the protective efficacy of a single dose adenovirus-vectored
170 e therefore evaluated the immunogenicity and protective efficacy of a single immunization of chimeric
173 Here, we examined the immunogenicity and protective efficacy of an aerosolized human parainfluenz
174 used an aged mouse model to investigate the protective efficacy of an attenuated WNV, the nonstructu
175 the dose-related safety, immunogenicity, and protective efficacy of an experimental trivalent influen
176 respiratory tract, allowing us to assess the protective efficacy of an H5N1 LAIV against highly patho
177 ate its ability to significantly improve the protective efficacy of an inactivated influenza virus va
178 udy provides the very first evidence for the protective efficacy of an intravaginal microbicide/vacci
180 ioluminescent imaging can be used to monitor protective efficacy of attenuated parasite immunizations
181 influences of PEM on the immunogenicity and protective efficacy of avian influenza A(H5N1) vaccine.
185 ting infection of mucosal tissues, while the protective efficacy of bnAbs targeting V1-V2 glycans (PG
187 he Salmonellagtr repertoire may confound the protective efficacy of broad-ranging Salmonella lipopoly
190 current study, we examined the long-lasting protective efficacy of chimeric VLPs (cVLPs) containing
192 s end, we demonstrate the immunogenicity and protective efficacy of FILORAB1, a recombinant, bivalent
194 the mouse model, we compared the inhibitory/protective efficacy of four mouse monoclonal antibodies
196 te the presence of Fc N-glycans enhances the protective efficacy of h-13F6, and that mAbs manufacture
197 We also evaluated the immunogenicity and protective efficacy of H5N1, H6N1, H7N3, and H9N2 ca vac
200 re the animal model of choice for evaluating protective efficacy of HIV/SIV vaccine candidates and th
202 del for investigating the immunogenicity and protective efficacy of human CD8(+) T cell epitope-based
207 is study, we examined the immunogenicity and protective efficacy of influenza VLPs (H1N1 A/PR/8/34) a
208 ted role of the microbiota in modulating the protective efficacy of intranasal vaccination through th
209 tudy, we investigated the immunogenicity and protective efficacy of IpaB and IpaD administered intrad
211 n in ferrets of the immunogenicity and cross-protective efficacy of isogenic mammalian cell-grown, li
213 and phenotypic specialization are linked to protective efficacy of memory T cells against reinfectio
214 oliovirus transmission in Uttar Pradesh, the protective efficacy of mOPV1 was estimated to be 30% (95
217 potential to improve the immunogenicity and protective efficacy of new and existing neonatal vaccine
218 ctive, and efficient method to determine the protective efficacy of new vaccines on pneumococcal colo
219 that the Hu-mouse can be used to predict the protective efficacy of novel tuberculosis vaccines/strat
222 ipid moieties enhance the immunogenicity and protective efficacy of pneumococcal TH17 antigens throug
223 different VEEV immunogens and evaluated the protective efficacy of purified preparations of the resu
225 vaccine priming did not further improve the protective efficacy of rAd5HVR48 vectors in this system.
228 n current study, we evaluated the safety and protective efficacy of recombinant unglycosylated RSV G
230 s may be a rapid approach for increasing the protective efficacy of seasonal vaccines in response to
235 In this article, we review data for the protective efficacy of the 2 new rotavirus vaccines, wit
237 end-of-study analysis of PATRICIA show cross-protective efficacy of the HPV-16/18 vaccine against fou
238 To test this assumption, changes in the protective efficacy of the immune response to B. burgdor
243 udy, we evaluated in parallel the safety and protective efficacy of the RSV A2 recombinant unglycosyl
244 e current study, we evaluated the safety and protective efficacy of the RSV A2 recombinant unglycosyl
245 urine CpG ODN 1826 on the immunogenicity and protective efficacy of the Saccharomyces cerevisiae-expr
246 aluated the differential immune response and protective efficacy of the Sal-Ag vaccine against challe
249 ion, the elicited antibody response, and the protective efficacy of the vaccines containing the DNA o
250 enously) revealed a marked difference in the protective efficacy of the various attenuated proviral v
251 vaccine in pigs (60%) and to the homologous protective efficacy of the VLP vaccine in humans (47%).
252 s study was to assess the immunogenicity and protective efficacy of the VSV-SRV serotype 2 vaccine pr
257 This difference may be of importance for the protective efficacy of these vaccination approaches agai
258 roteins and evaluated the immunogenicity and protective efficacy of these vaccine candidates in mice
262 the Th17 adjuvant curdlan, and we tested the protective efficacy of vaccination in a murine model of
263 LR2/6, TLR3, and TLR9) greatly increased the protective efficacy of vaccination with an HIV envelope
264 of tuberculous meningitis, we evaluated the protective efficacy of vaccination with the recombinant
265 e boosting antigen impacts the magnitude and protective efficacy of vaccine-elicited immune responses
266 tamin A deficiency on the immunogenicity and protective efficacy of vaccines has not been defined pre
267 osa pneumonia to assess the contributions to protective efficacy of various bacterial antigens and ho
271 d with decreased risk of neonatal mortality (protective efficacy [PE] 18%, 95% CI 4-30; incidence rat
272 tected against moderate-to-severe diarrhoea (protective efficacy [PE] 75%, p=0.0070) and severe diarr
277 adjuvants based on their immune profiles and protective efficacy to inform a rational development of
279 ruses influenced HAI-specific antibodies and protective efficacy using a broadly protective vaccine c
281 In this study, we present data on safety and protective efficacy using sporozoites with deletions of
282 ated whole-virus vaccines and compared their protective efficacy versus that of antigens from positiv
292 imeric Plasmodium yoelii proteins to enhance protective efficacy, we designed PvRMC-CSP, a recombinan
295 e molecularly defined lipopeptides and their protective efficacy were assessed, in terms of virus rep
296 FdU) and examined their immunogenicities and protective efficacies when administered alone or followe
298 n, promoting thermal resilience and enhanced protective efficacy, which may be important in its use a
299 30, has since been shown to also demonstrate protective efficacy with a delayed treatment start.
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。